2022
Assessment of Clinical Effectiveness of BNT162b2 COVID-19 Vaccine in US Adolescents
Oliveira CR, Niccolai LM, Sheikha H, Elmansy L, Kalinich CC, Grubaugh ND, Shapiro ED, Billig K, Breban M, Brito A, Earnest R, Fauver J, Koch T, Ott I, Petrone M, Vogels C, Pham K, Tikhonova I, Castaldi C, Mane S, Bilguvar K, De Kumar B, Ferguson D, Kerantzas N, Landry M, Peaper D, Schulz W. Assessment of Clinical Effectiveness of BNT162b2 COVID-19 Vaccine in US Adolescents. JAMA Network Open 2022, 5: e220935. PMID: 35238933, PMCID: PMC8895259, DOI: 10.1001/jamanetworkopen.2022.0935.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionCase-control studyVaccine effectivenessBNT162b2 vaccineSARS-CoV-2Medical recordsAsymptomatic SARS-CoV-2 infectionBNT162b2 COVID-19 vaccineRetrospective case-control studyRT-PCR test resultsSARS-CoV-2 testUS adolescentsReverse transcription polymerase chain reaction testConditional logistic regression modelsTranscription polymerase chain reaction testDoses of vaccineControl participantsClinical trial populationsRelevant clinical dataCase participantsCOVID-19 vaccinePositive test resultsChain reaction testCounty of residenceNegative test results
2021
Patterns of recommended vaccine receipt among women ages 24–45 years: a cross-sectional analysis
Ellingson MK, Oliveira CR, Sheth SS, Sullivan EL, Torres A, Shapiro ED, Niccolai LM. Patterns of recommended vaccine receipt among women ages 24–45 years: a cross-sectional analysis. BMC Public Health 2021, 21: 1283. PMID: 34193100, PMCID: PMC8247221, DOI: 10.1186/s12889-021-11340-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultCase-Control StudiesCross-Sectional StudiesFemaleHumansInfluenza VaccinesMiddle AgedPapillomavirus VaccinesVaccinationYoung AdultConceptsMid-adult womenVaccine receiptCross-sectional analysisHPV vaccineOngoing case-control studyReceipt of influenzaHealth care visitsCase-control studyWomen ages 24Quarter of adultsLogistic regression analysisCare visitsIndividual vaccinesHealthcare utilizationMultiple vaccinesVaccineAge 24White womenWomenDemographic characteristicsRegression analysisLower ratesInfluenzaReceiptPast yearEffectiveness of HPV vaccine by age at vaccination and number of doses: protocol for a population-based matched case–control study
Oliveira CR, Ortiz AM, Sheth SS, Shapiro ED, Niccolai LM. Effectiveness of HPV vaccine by age at vaccination and number of doses: protocol for a population-based matched case–control study. BMJ Open 2021, 11: e043093. PMID: 33875441, PMCID: PMC8057558, DOI: 10.1136/bmjopen-2020-043093.Peer-Reviewed Case Reports and Technical NotesMeSH KeywordsCase-Control StudiesFemaleHumansPapillomavirus InfectionsPapillomavirus VaccinesUterine Cervical NeoplasmsVaccinationConceptsHigh-grade cervical lesionsPre-licensure clinical trialsHPV vaccineCase-control studyNumber of dosesClinical trialsFirst human papillomavirus (HPV) vaccineMultivariate conditional logistic regressionNormal Pap test resultsReal-world clinical settingHuman papillomavirus vaccinePap test resultsHPV types 16Time of immunisationReal-world effectivenessConditional logistic regressionInstitutional review boardDate of testingPapillomavirus vaccineCervical lesionsPotential confoundersVaccine programMedical recordsPersistent infectionType 16